Between the beginning of January 2020 and June 14, 2023, of the 1,134,641 deaths caused by COVID-19 in the United States, around 307,169 had occurred among those aged 85 years and older. This statistic shows the number of coronavirus disease 2019 (COVID-19) deaths in the U.S. from January 2020 to June 2023, by age.

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Deaths involving coronavirus disease 2019 (COVID-19) with a focus on ages 0-18 years in the United States.

In 2023, the leading causes of death for children aged one to four years in the United States were unintentional injuries and congenital malformations, deformations, and chromosomal abnormalities. At that time, around 31 percent of all deaths among these children were caused by unintentional injuries. Differences in causes of death among children by age Just as unintentional injuries are the leading cause of death among children aged one to four, it is also the leading cause of death for the age groups five to nine and 10 to 14. However, congenital malformations, deformations, and chromosomal abnormalities account for fewer deaths as children become older, while the share of deaths caused by cancer is higher among those aged five to nine and 10 to 14. In fact, cancer is the second leading cause of death among five to nine-year-olds, accounting for around 16 percent of all deaths. Sadly, the second leading cause of death among children aged 10 to 14 is intentional self-harm, with 14 percent of all deaths among those in this age group caused by suicide. Leading causes of death in the United States The leading causes of death in the United States are heart disease and malignant neoplasms. Together, these two diseases accounted for around 42 percent of all deaths in the United States in 2023. In 2023, the lifetime odds that the average person in the United States would die from heart disease was one in six, while the odds for cancer were one in seven.

Abstract Objectives: to describe epidemiological characteristics and deaths in children with cancer and COVID-19 at a reference hospital in Recife, Brazil. Methods: cohort involving children under the age of 19 underwent cancer treatment during April to July 2020. During the pandemic, real-time reverse transcriptase polymerase chain reaction assay (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2) in nasal / oropharyngeal swab were collected in symptomatic patients or before hospitalization. Those with detectable results were included in this cohort study. The outcomes were delayed on cancer treatment and death. Descriptive analysis was performed and presented in preliminary results. Results: 48 children participated in the cohort, mostly with hematological neoplasms (66.6%.),69% were male, median age was 5.5 years. The most frequent symptoms were fever (58.3%) and coughing (27.7%);72.9% required hospitalization, 20% had support in ICU and 10.5% on invasive ventilatory assistance.66.6% of the patients had their oncological treatment postponed, 16.6% died within 60 days after confirmation of SARS-CoV-2 infection. Conclusions: COVID-19 led a delay in the oncological treatment for children with cancer and a higher mortality frequency when compared to the historical series of the service. It would be important to analyze the risk factors to determine the survival impact.

Mode of data collection

Other [oth]

IntroductionRecent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines' pathogen-specific effects, but less than a handful focus on NSE. This paper addresses that gap by reporting economic evaluations of the NSE of oral polio vaccine (OPV) against under-five mortality and COVID-19.Materials and methodsWe studied two settings: (1) reducing child mortality in a high-mortality setting (Guinea-Bissau) and (2) preventing COVID-19 in India. In the former, the intervention involves three annual campaigns in which children receive OPV incremental to routine immunization. In the latter, a susceptible-exposed-infectious-recovered model was developed to estimate the population benefits of two scenarios, in which OPV would be co-administered alongside COVID-19 vaccines. Incremental cost-effectiveness and benefit-cost ratios were modeled for ranges of intervention effectiveness estimates to supplement the headline numbers and account for heterogeneity and uncertainty.ResultsFor child mortality, headline cost-effectiveness was $650 per child death averted. For COVID-19, assuming OPV had 20% effectiveness, incremental cost per death averted was $23,000–65,000 if it were administered simultaneously with a COVID-19 vaccine <200 days into a wave of the epidemic. If the COVID-19 vaccine availability were delayed, the cost per averted death would decrease to $2600–6100. Estimated benefit-to-cost ratios vary but are consistently high.DiscussionEconomic evaluation suggests the potential of OPV to efficiently reduce child mortality in high mortality environments. Likewise, within a broad range of assumed effect sizes, OPV (or another vaccine with NSE) could play an economically attractive role against COVID-19 in countries facing COVID-19 vaccine delays.FundingThe contribution by DTJ was supported through grants from Trond Mohn Foundation (BFS2019MT02) and Norad (RAF-18/0009) through the Bergen Center for Ethics and Priority Setting.

Throughout the depicted period in Panama, the rate of child mortality exhibited an initial increase, subsequently showcasing a downward trend, particularly during the COVID-19 pandemic, where it experienced a significant decline, hitting its nadir in 2020 at ****.

BackgroundThe SARS-CoV-2 pandemic remains a critical global health concern, with older adults being the most vulnerable group. Nonetheless, it is crucial to recognize that COVID-19 has caused numerous deaths in children worldwide. Emerging evidence indicates that infants and breastfeeding children, particularly those aged below one year, face a greater risk of hospitalization and mortality than older children with COVID-19.ObjectiveThis study aimed to describe the epidemiology of COVID-19 among children during the early phase of the pandemic in Ecuador.MethodsWe conducted a country-wide population-based analysis of the epidemiology of COVID-19, using incidence and mortality data reported from Ecuador between February 15, 2020 and May 14 2021. Measurements of frequency, central tendency, dispersion, and absolute differences were calculated for all categorical and continuous variables.ResultsAt least 34,001 cases (23,587 confirmed cases, 5,315 probable and 5,099 suspected) and 258 COVID-19 related deaths have been reported among children in Ecuador during the first 16 months of the pandemic. The overall incidence rate was 612 cases per 100,000 children, the mortality rate was 3 per 100,000, while the case fatality rate was 0.76%. The highest risk group for infection was children and adolescents between 15 and 19 years of age; however, the highest mortality rate occurred in children under one year of age. The largest provinces, such as Pichincha, Guavas and Manabí, were the ones that reported the highest number of cases, 27%, 12.1% and 10.8%, respectively.ConclusionsThis study is the first to report on COVID-19 epidemics among children in Ecuador. Our findings reveal that younger children have a lower risk of SARS-CoV-2 infection, but a higher risk of mortality compared to older children and adolescents. Additionally, we observed significant disparities in infection rates and outcomes among children living in rural areas, those with comorbidities, and those from indigenous ethnic groups.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by sex, age group, and jurisdiction of occurrence.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Abstract Objectives: to characterize school-aged children, adolescents, and young people’s profile and their associations with positive COVID-19 test results. Methods: an observational and descriptive study of secondary data from the COVID-19 Panel in Espírito Santo State in February to August 2020. People suspected of COVID-19, in the 0–19-years old age group, were included in order to assess clinical data and demographic and epidemiological factors associated with the disease. Results: in the study period, 27,351 COVID-19 notification were registered in children, adolescents, and young people. The highest COVID-19 test confirmation was found in Caucasians and were 5-14 years age group. It was also observed that headache was the symptom with the highest test confirmation. Infection in people with disabilities was more frequent in the confirmed cases. The confirmation of cases occurred in approximately 80% of the notified registrations and 0.3% of the confirmed cases, died. Conclusion: children with confirmed diagnosis for COVID-19 have lower mortality rates, even though many were asymptomatic. To control the chain of transmission and reduce morbidity and mortality rates, it was necessaryto conduct more comprehensive research and promote extensive testing in the population.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

As of January 11, 2023, the highest number of deaths due to the coronavirus in Sweden was among individuals aged 80 to 90 years old. In this age group there were 9,124 deaths as a result of the virus. The overall Swedish death toll was 22,645 as of January 11, 2023.

The first case of coronavirus (COVID-19) in Sweden was confirmed on February 4, 2020. The number of cases has since risen to over 2.68 million, as of January 2023. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Note: Data elements were retired from HERDS on 10/6/23 and this dataset was archived.

This dataset includes the cumulative number and percent of healthcare facility-reported fatalities for patients with lab-confirmed COVID-19 disease by reporting date and age group. This dataset does not include fatalities related to COVID-19 disease that did not occur at a hospital, nursing home, or adult care facility. The primary goal of publishing this dataset is to provide users with information about healthcare facility fatalities among patients with lab-confirmed COVID-19 disease.

The information in this dataset is also updated daily on the NYS COVID-19 Tracker at https://www.ny.gov/covid-19tracker.

The data source for this dataset is the daily COVID-19 survey through the New York State Department of Health (NYSDOH) Health Electronic Response Data System (HERDS). Hospitals, nursing homes, and adult care facilities are required to complete this survey daily. The information from the survey is used for statewide surveillance, planning, resource allocation, and emergency response activities. Hospitals began reporting for the HERDS COVID-19 survey in March 2020, while Nursing Homes and Adult Care Facilities began reporting in April 2020. It is important to note that fatalities related to COVID-19 disease that occurred prior to the first publication dates are also included.

The fatality numbers in this dataset are calculated by assigning age groups to each patient based on the patient age, then summing the patient fatalities within each age group, as of each reporting date. The statewide total fatality numbers are calculated by summing the number of fatalities across all age groups, by reporting date. The fatality percentages are calculated by dividing the number of fatalities in each age group by the statewide total number of fatalities, by reporting date. The fatality numbers represent the cumulative number of fatalities that have been reported as of each reporting date.

World health statistics 2023: monitoring health for the SDGs, sustainable development goals

Overview

The World health statistics report is the annual compilation of health and health-related indicators which has been published by the World Health Organization (WHO) since 2005.

The 2023 edition reviews more than 50 health-related indicators from the Sustainable Development Goals (SDGs) and WHO’s Thirteenth General Programme of Work (GPW 13)

The report summarizes the trends in life expectancy and causes of death, and reports on progress towards the health-related Sustainable Development Goals (SDGs) and associated targets.

https://cdn.who.int/media/images/default-source/ddi-department/world-health-statistics-report-2023/01-who_mca-danangkmc-vnm-(22-of-37).tmb-1366v.jpg?sfvrsn=cb53a2df_1" alt="test">

Annual rate of reduction in maternal and child mortality has dropped in recent years

https://cdn.who.int/media/images/default-source/ddi-department/world-health-statistics-report-2023/778-whs-2023-visual-summary_message-1_230505.svg?sfvrsn=f80e927a_4" alt="">

Without faster progress, no regions will achieve the SDG target for NCD mortality by 2030 – and half still won’t by 2048

https://cdn-auth-cms.who.int/media/images/default-source/ddi-department/world-health-statistics-report-2023/km2_western-pacific.svg" alt="">

Total years of life lost due to COVID-19 by age-group

https://cdn-auth-cms.who.int/media/images/default-source/ddi-department/world-health-statistics-report-2023/km4_western-pacific.svg" alt="">

Acknowledgements

This Dataset is created from https://www.who.int/ . If you want to learn more, you can visit the Website.

As of April 26, 2023, around 27 percent of total COVID-19 deaths in the United States have been among adults 85 years and older, despite this age group only accounting for two percent of the U.S. population. This statistic depicts the distribution of total COVID-19 deaths in the United States as of April 26, 2023, by age group.

The coronavirus (COVID-19) has led to over 183,000 deaths in Germany, as of 2024. When looking at the distribution of deaths by age, based on the figures currently available, most death occurred in the age group 80 years and older at approximately 118,938 deaths.

Provisional counts of the number of deaths and age-standardised mortality rates involving the coronavirus (COVID-19) between 1 March and 17 April 2020 in England and Wales. Figures are provided by age, sex, geographies down to local authority level and deprivation indices.

BackgroundDespite children and young people (CYP) having a low risk for severe coronavirus disease 2019 (COVID-19) outcomes, there is still a degree of uncertainty related to their risk in the context of immunodeficiency or immunosuppression, primarily due to significant reporting bias in most studies, as CYP characteristically experience milder or asymptomatic COVID-19 infection and the severe outcomes tend to be overestimated.MethodsA comprehensive systematic review to identify globally relevant studies in immunosuppressed CYP and CYP in general population (defined as younger than 25 years of age) up to 31 October 2021 (to exclude vaccinated populations) was performed. Studies were included if they reported the two primary outcomes of our study, admission to intensive therapy unit (ITU) and mortality, while data on other outcomes, such as hospitalization and need for mechanical ventilation were also collected. A meta-analysis estimated the pooled proportion for each severe COVID-19 outcome, using the inverse variance method. Random effects models were used to account for interstudy heterogeneity.FindingsThe systematic review identified 30 eligible studies for each of the two populations investigated: immunosuppressed CYP (n = 793) and CYP in general population (n = 102,022). Our meta-analysis found higher estimated prevalence for hospitalization (46% vs. 16%), ITU admission (12% vs. 2%), mechanical ventilation (8% vs. 1%), and increased mortality due to severe COVID-19 infection (6.5% vs. 0.2%) in immunocompromised CYP compared with CYP in general population. This shows an overall trend for more severe outcomes of COVID-19 infection in immunocompromised CYP, similar to adult studies.InterpretationThis is the only up-to-date meta-analysis in immunocompromised CYP with high global relevance, which excluded reports from hospitalized cohorts alone and included 35% studies from low- and middle-income countries. Future research is required to characterize individual subgroups of immunocompromised patients, as well as impact of vaccination on severe COVID-19 outcomes.Systematic Review RegistrationPROSPERO identifier, CRD42021278598.

Herein, we report a child with COVID-19 and seemingly no underlying disease, who died suddenly. The autopsy revealed severe anemia and thrombocytopenia, splenomegaly, hypercytokinemia, and a rare ectopic congenital coronary origin. Immunohistochemical analysis demonstrated that the patient had acute lymphoblastic leukemia of the B-cell precursor phenotype (BCP-ALL). The complex cardiac and hematological abnormalities suggested the presence of an underlying disease; therefore, we performed whole-exome sequencing (WES). WES revealed a leucine-zipper-like transcription regulator 1 (LZTR1) variant, indicating Noonan syndrome (NS). Therefore, we concluded that the patient had underlying NS along with coronary artery malformation and that COVID-19 infection may have triggered the sudden cardiac death due to increased cardiac load caused by high fever and dehydration. In addition, multiple organ failure due to hypercytokinemia probably contributed to the patient’s death. This case would be of interest to pathologists and pediatricians because of the limited number of NS patients with LZTR1 variants; the complex combination of an LZTR1 variant, BCP-ALL, and COVID-19; and a rare pattern of the anomalous origin of the coronary artery. Thus, we highlight the significance of molecular autopsy and the application of WES with conventional diagnostic methods.